I think most shareholders would be enormously excited if there any sort of dep licensing deal within the next 12 months. it would be an enormous catalyst to the share price and validation for the technology...... and therein lies the problem IMO given we have been told for years that the company is in 'commercial in confidence discussions with multiple potential partners' to license our DEP drugs - If the science is as good as many constantly claim on here, why doesn't any one want it, especially now that multiple phase 2 trials have taken place and data released ?
However ..... I do see
some positives / glimmer of hope ....
1. We have $25 million in the bank so likely funded for another 12 months; and
2. AG have supposedly finished selling their Substantial Holding; and
3. There is only 418,107,037 shares on issue; and
4. Cheryl may get some sort of license deal up but it won't be for anything like
@antibotter has boasted for years of $100 million for each drug, but it would at least validate the science in some way; and
5. Medicxi 'may' deliver the goods on whatever it is they are researching / running with if Starpharma ever disclose to the market just what that is ?
These key catalysts '
could' see some value return to the share price over the next 12 months if they succeed but I can't see us rising to anywhere near previous levels even if they all came to fruition
The AGM should be a hoot ...... lol
GLTAH
(20min delay)